Kymos Pharma Services SL (commonly known as Kymos) is a contract research organization (CRO) based in Spain, providing specialized analytical and bioanalytical laboratory services to the pharmaceutical, biotechnology, and related life sciences industries. Headquartered in the Barcelona metropolitan area, specifically in Cerdanyola del Vallès within the Barcelona Synchrotron Park (Parc de l'Alba), Kymos has established itself as a trusted partner supporting drug development programs from early-stage research through to commercial manufacturing and quality control.
The company operates as an independent CRO offering GMP (Good Manufacturing Practice) and GLP (Good Laboratory Practice) compliant services. Over the years, Kymos has grown its capabilities and geographic footprint, positioning itself as a comprehensive analytical services provider capable of supporting complex drug development challenges across a wide range of therapeutic modalities.
Core Business Focus
Kymos concentrates on providing outsourced analytical, bioanalytical, and pharmaceutical development services. The company serves clients who need specialized scientific expertise and regulated laboratory infrastructure without having to develop these capabilities in-house. Its work supports every phase of the drug development lifecycle, including preclinical research, clinical trials, and post-approval commercial support.
The organization emphasizes quality, regulatory compliance, and scientific rigor. Its laboratories operate under internationally recognized quality standards, and the company is subject to inspections and audits from regulatory authorities and clients alike. This regulatory compliance is central to Kymos's value proposition, since pharmaceutical companies depend on reliable, defensible data to progress their products through regulatory approval processes.
Services Offered
Analytical Development and Quality Control
Kymos provides analytical method development, validation, and transfer services for pharmaceutical products. These services include the design and optimization of analytical procedures used to characterize drug substances and drug products. The company performs quality control testing for raw materials, intermediates, active pharmaceutical ingredients (APIs), and finished pharmaceutical products.
Its analytical work encompasses techniques such as high-performance liquid chromatography (HPLC), ultra-high-performance liquid chromatography (UHPLC), gas chromatography (GC), mass spectrometry, spectroscopy, and various other physicochemical characterization methods. These capabilities support the identification, quantification, and purity assessment of compounds.
Bioanalysis
A significant part of Kymos's expertise lies in bioanalytical services, which involve the measurement of drugs and their metabolites in biological matrices such as plasma, serum, urine, and tissue. These analyses are critical for pharmacokinetic (PK) and toxicokinetic (TK) studies. The company uses liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) and ligand-binding assays to support both small molecules and larger biological therapeutics.
Bioanalytical services support preclinical and clinical studies, providing the data needed to understand how a drug is absorbed, distributed, metabolized, and eliminated in the body.
Stability Studies
Kymos offers stability testing services in accordance with ICH (International Council for Harmonisation) guidelines. These studies assess how the quality of a drug substance or drug product varies over time under the influence of environmental factors such as temperature and humidity. The company maintains stability chambers under controlled conditions to conduct long-term, intermediate, accelerated, and stress stability studies, helping clients establish shelf life and appropriate storage conditions for their products.
Impurities and Elemental Analysis
The company provides identification and characterization of impurities, including organic impurities, degradation products, and genotoxic impurities. Kymos also performs elemental impurity analysis in line with regulatory expectations such as ICH Q3D, using techniques like inductively coupled plasma mass spectrometry (ICP-MS). Nitrosamine testing has also become an important area of analytical focus for CROs like Kymos, addressing regulatory concerns about these potentially harmful impurities.
Biologics and Large Molecule Characterization
Kymos supports the growing biologics and biosimilars market by offering characterization services for proteins, peptides, antibodies, and other complex biological molecules. These services involve techniques for assessing structure, purity, aggregation, glycosylation, and other critical quality attributes essential for biological drug products.
Extractables and Leachables
The company conducts extractables and leachables (E&L) studies, which evaluate potential chemical compounds that may migrate from container closure systems, packaging, or manufacturing equipment into a drug product. These studies are important for ensuring patient safety and product integrity.
Medical Devices and Combination Products
Kymos provides testing services relevant to medical devices and drug-device combination products, addressing the increasingly complex regulatory landscape that governs these product categories.
Quality and Regulatory Compliance
Kymos operates its facilities in compliance with GMP and GLP standards. The company holds certifications and authorizations from relevant regulatory bodies and has been inspected by agencies such as the Spanish Agency of Medicines and Medical Devices (AEMPS) and the U.S. Food and Drug Administration (FDA). This regulatory recognition allows the company to support products intended for markets worldwide.
The company's commitment to data integrity, quality systems, and adherence to international guidelines makes it a reliable partner for pharmaceutical companies navigating strict regulatory requirements.
Markets and Clientele
Kymos serves a diverse client base that includes multinational pharmaceutical companies, small and medium-sized biotech firms, generic drug manufacturers, and biosimilar developers. Its clients span multiple geographic regions, with the company supporting development programs intended for European, North American, and other international markets.
By offering a broad portfolio of analytical and bioanalytical services under one roof, Kymos enables clients to consolidate their outsourcing needs and benefit from integrated project management and scientific consistency.
Growth and Expansion
Over the years, Kymos has expanded both its service offerings and its physical presence. The company has grown from its Spanish base to establish additional laboratory capabilities and presence in other locations, reflecting increasing demand for its services and a strategy of geographic and scientific diversification. This growth has allowed Kymos to serve a broader client base and offer enhanced capabilities across multiple therapeutic and technical areas.
Conclusion
Kymos Pharma Services SL is a specialized contract research organization that plays an important role in the pharmaceutical and biotechnology value chain. Through its analytical, bioanalytical, stability, and characterization services, the company supports the development, testing, and quality control of medicines and biological products. Its emphasis on regulatory compliance, scientific expertise, and comprehensive service offerings positions Kymos as a valued partner for companies seeking to advance drug candidates and maintain the quality of marketed products. As the life sciences industry continues to evolve toward more complex therapeutic modalities, Kymos remains focused on delivering reliable, high-quality analytical solutions to meet the needs of a demanding and highly regulated market.
